Featured Research

from universities, journals, and other organizations

Novel Herbal Therapy For Men At High Risk Of Prostate Cancer Well-Tolerated In Phase I Trial

Date:
May 25, 2009
Source:
Columbia University Medical Center
Summary:
Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

Results of a phase I clinical trial of a novel herb-based therapeutic called Zyflamend have demonstrated that the therapy is associated with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer.

Related Articles


The new findings, led by researchers from the Center for Holistic Urology at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia, are published in the current issue of the Journal of the Society for Integrative Oncology.

In the study, 23 men ages 40-75 years-old who were diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN) at biopsy, lesions that indicate an increased risk of developing prostate cancer, were admitted into this prospective clinical trial, in order to determine the safety and tolerability of Zyflamend when administered orally for 18-months, either alone or along with various dietary supplements.

"Since we know that men with HGPIN have an increased risk for developing prostate cancer, new strategies formulated to decrease cancer risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial for these men," said Aaron E. Katz, M.D., senior author of the study. He is associate professor of urology at Columbia University College of Physicians and Surgeons, director of the Center of Holistic Urology at Columbia University Medical Center and a urologist at NewYork-Presbyterian/Columbia.

Basic science studies have indicated that Zyflamend may have an anti-inflammatory mechanism of action and the agent has been shown to decrease prostate cancer proliferation in cell culture.

"Our results confirm that Zyflamend, in a dose of three times daily for up to 18-months, was well tolerated," said Jillian L. Capodice, M.S., director of the Acupuncture Research and Integrative Clinical Service of the Department of Urology's Center for Holistic Urology, at Columbia University College of Physicians and Surgeons.

Prostate cancer is a cancer that forms in tissues of the prostate (a gland in the male reproductive system found below the bladder and in front of the rectum). Prostate cancer usually occurs in older men. The National Cancer Institute estimates that in 2009 there will be 192,280 new cases of prostate cancer diagnosed and 27,360 deaths attributed to prostate cancer in the United States.


Story Source:

The above story is based on materials provided by Columbia University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University Medical Center. "Novel Herbal Therapy For Men At High Risk Of Prostate Cancer Well-Tolerated In Phase I Trial." ScienceDaily. ScienceDaily, 25 May 2009. <www.sciencedaily.com/releases/2009/05/090522154508.htm>.
Columbia University Medical Center. (2009, May 25). Novel Herbal Therapy For Men At High Risk Of Prostate Cancer Well-Tolerated In Phase I Trial. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2009/05/090522154508.htm
Columbia University Medical Center. "Novel Herbal Therapy For Men At High Risk Of Prostate Cancer Well-Tolerated In Phase I Trial." ScienceDaily. www.sciencedaily.com/releases/2009/05/090522154508.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Microsoft Launches Fitness Band After Accidental Reveal

Microsoft Launches Fitness Band After Accidental Reveal

Newsy (Oct. 30, 2014) Microsoft accidentally revealed its upcoming fitness band on Wednesday, so the company went ahead and announced it. Video provided by Newsy
Powered by NewsLook.com
Bracing to Meet a Killer: Aid Workers Prep for Ebola in Geneva

Bracing to Meet a Killer: Aid Workers Prep for Ebola in Geneva

AFP (Oct. 30, 2014) At the International Federation of Red Cross and Red Crescent Societies, around 30 doctors, nurses, lab technicians and water and sanitation workers are gathered for a crash-course in how to safely deal Ebola. Duration: 01:31 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins